Apollo Health Ventures

Apollo Ventures is an early-stage investment firm based in Berlin, Germany, founded in 2016. The firm is dedicated to accelerating scientific breakthroughs in the life sciences by establishing companies that focus on innovative therapeutic technologies. Apollo Ventures targets investments in assets that have the potential to treat, prevent, or reverse age-related diseases, including Alzheimer's, heart disease, sarcopenia, frailty, and cancer, with the aim of extending healthy human lifespan. The firm collaborates with scientists and entrepreneurs to create new ventures and engages in hypothesis-driven company building within the biotechnology, data platforms, therapeutics, and health-tech sectors.

Jan Adams

Partner

Laurent Audoly Ph.D

Executive Partner

Kevin Dong

Venture Analyst

Steven Leunert Ph.D

CFO and Partner

Inés Simó

Venture Analyst

Anela Vukoja

COO

Christopher Shepard Ph.D

Venture Partner

Anela Vukoja Ph.D

COO

18 past transactions

Auron Therapeutics

Series B in 2025
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Refoxy Pharma

Seed Round in 2024
Refoxy Pharma develops therapeutic medicines aimed at treating age-related diseases and promoting healthy longevity. The company studies FOXO proteins that regulate genes involved in stress resistance and metabolism, and works on novel modulators of a central stress response pathway to influence aging through genetics, with the goal of extending the years of healthy living for patients.

Booster Therapeutics

Seed Round in 2024
Booster Therapeutics is a biotechnology company focused on developing drug modalities to regulate cellular homeostasis and eliminate toxic accumulations. Its primary goal is to reinstate balance within cells, enabling the prevention and treatment of diseases associated with aging.

Aeovian Pharmaceuticals

Series A in 2024
Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.

Cleara Biotech

Seed Round in 2022
Cleara Biotech B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative therapeutics to selectively eliminate senescent and senescent-like cancer cells. The company specializes in creating FOXO4-based anti-senescence drugs aimed at addressing chemotoxicity and combating therapy-resistant cancer cells. Cleara Biotech's research targets a crucial aspect of cancer treatment by aiming to enhance the effectiveness of therapies and improve patient outcomes through the targeted removal of problematic cell populations.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

HAYA Therapeutics

Seed Round in 2022
HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Bloom Science

Series A in 2021
Bloom Science, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing neuroprotective therapies leveraging the microbiome to treat epilepsy and other neurological disorders. Founded in 2017, the company employs its proprietary IrisRx™ platform to explore innovative treatments that target the Gut-Brain Axis, aiming to create therapeutics with enhanced safety profiles. Bloom Science's approach focuses on harnessing gut commensal microbes and integrating insights from synthetic biology to develop multi-functional therapeutics. The company is advancing a robust pipeline of programs addressing complex conditions such as Dravet syndrome, various rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders, with the goal of delivering transformative solutions for patients facing serious, life-altering illnesses.

Ochre Bio

Seed Round in 2021
Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.

HAYA Therapeutics

Seed Round in 2021
HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics

Seed Round in 2021
HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Samsara Therapeutics

Seed Round in 2019
Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Aeovian Pharmaceuticals

Series A in 2019
Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.

Samsara Therapeutics

Seed Round in 2019
Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Cleara Biotech

Seed Round in 2018
Cleara Biotech B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative therapeutics to selectively eliminate senescent and senescent-like cancer cells. The company specializes in creating FOXO4-based anti-senescence drugs aimed at addressing chemotoxicity and combating therapy-resistant cancer cells. Cleara Biotech's research targets a crucial aspect of cancer treatment by aiming to enhance the effectiveness of therapies and improve patient outcomes through the targeted removal of problematic cell populations.

Aeovian Pharmaceuticals

Seed Round in 2017
Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.

HAYA Therapeutics

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Therini Bio

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.